In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organon Kicks Off Partnering Strategy with Pfizer Deal

Executive Summary

Hard times at drug division Organon have forced Akzo Nobel to cut costs and restructure. As part of this effort, the Dutch conglomerate has implemented an aggressive partnering strategy to maximize the value of its late-stage pharma pipeline. Its potential $370 million pact with Pfizer for the Phase II/III antipsychotic asenapine marks an impressive start, and underscores Akzo's commitment to rebuilding Organon.

You may also be interested in...



Schering-Plough Adds to Pipeline with Organon Acquisition

In a bold move it says will bolster its late-stage pipeline and provide necessary scale in sales and biologics manufacturing, Schering-Plough Corp. is acquiring the CNS and women's health specialist Organon BioSciences from Dutch conglomerate Akzo Nobel for $14.4 billion. For the acquisition to be a success, SP will have to find value where others have not--specifically in Organon's Phase III schizophrenia treatment asenapine, which was handed back to the company by Pfizer after disappoinging clinical results.

Organon Reboots with Biotech

Organon's biologics R&D push relects similar moves by other mid-sized firms, and could help the company recover after a series of setbacks. But building biotech from discovery upwards will take time.

Akzo Pharma's Fall and Rise

The recent meltdown at Akzo Nobel's Pharma unit was caused by a perfect storm of genericization, macroeconomic gloom, pipeline delays and product underperformance. But Akzo Pharma hopes that by beefing up R&D and cutting costs through restructuring, it can return to growth in 2005.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel